- AUD/USD remains on the front-foot while refreshing the multi-day high.
- Downbeat US GDP, FOMC updates join optimism surrounding Gilead’s Remdesivir.
- Upbeat Aussie data the previous data also takes part in cheering broad US dollar weakness.
- China’s official PMIs, second-tier Australian economic data will decorate the calendar, virus updates remain as important.
AUD/USD bulls keep the helm while taking the bids to 0.6555, with the recent high of 0.6559, at the start of Thursday’s Asian session. In doing so, the Aussie pair stretches the latest gains to refresh seven-week top while cheering weak US dollar, amid downbeat US catalysts, as well as optimism concerning the coronavirus (COVID-19) drug discovery.
US GDP drops, Fed conveys pandemic fears and stays ready for further action…
The preliminary reading of the US first quarter (Q1) GDP slumped more than expected -4% to -4.8%, the sharpest fall since the Great Financial Crisis (GFC). The growth figures marked +2.1% prior to Q4 2019. Even so, some in the street anticipated higher than the actual loss to the GDP.
The US Federal Reserve (Fed) didn’t step back from conveying that the current health crisis poses considerable risks to the economic outlook over the medium term. The Fed policymakers also showed readiness to do “whatever it takes” with Chairman Jerome Powell matching wide expectations of being worried and conveying the fears. It’s worth mentioning that the Fed didn’t alter its monetary policy amid all, as anticipated, during Wednesday’s meeting.
Gilead’s Remdesivir adds strength to risk-on…
With the market’s keen search for the epidemic’s cure, news that Gilead’s experimental drug Remdesivir cut the time to recover from COVID-19 and showed evidence of blocking the virus propelled the risk-on sentiment. The development helped US President Donald Trump to reiterate his push for the vaccine and be the man to save the world. As per the CNBC, US President Trump wants FDA to move as quickly as they can on Remdesivir coronavirus approval.
As a result, the US 10-year Treasury yields gain two basis points (bps) to 0.63% whereas Wall Street closed Wednesday with over 2.0% gains each by the key benchmarks.
Looking forward, China’s official figures for April month Manufacturing and Non-Manufacturing PMI will be the key to watch ahead of the Aussie Q1 Import and Export Price Index as well as March month Private Sector Credit. The key data, China Manufacturing PMI, is likely to soften from the previous 52 to 51, while further weakness is expected in the Aussie data. However, Chinese figures might surprise to the upside considering the economy’s return from the virus lockdowns, which in turn can please the bulls. It should also be noted that the Aussie CPI for the first quarter (Q1) has been upbeat and hence may help provide welcome surprises to the Aussie data watchers. Other than the calendar, virus updates will also be the key.
100-day SMA near 0.6570 is still standing tall to challenge the Aussie buyers. Though, sellers will refrain entries unless breaking mid-month high close to 0.6445/40.
additional important levels
|Today last price||0.6558|
|Today Daily Change||67 pips|
|Today Daily Change %||1.03%|
|Today daily open||0.6491|
|Previous Daily High||0.6515|
|Previous Daily Low||0.6434|
|Previous Weekly High||0.6406|
|Previous Weekly Low||0.6253|
|Previous Monthly High||0.6686|
|Previous Monthly Low||0.5509|
|Daily Fibonacci 38.2%||0.6484|
|Daily Fibonacci 61.8%||0.6465|
|Daily Pivot Point S1||0.6444|
|Daily Pivot Point S2||0.6398|
|Daily Pivot Point S3||0.6363|
|Daily Pivot Point R1||0.6526|
|Daily Pivot Point R2||0.6561|
|Daily Pivot Point R3||0.6607|
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.